Advertisement

Topics

Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs

15:23 EDT 18 Aug 2017 | SCRIP

Peregrine, Ardelyx, Egalet and others reduced expenses and sought alternatives in the second quarter. Also, cell and gene therapy investment...

      

Related Stories

 

Original Article: Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs

NEXT ARTICLE

More From BioPortfolio on "Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...